PROTONIX IV
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PROTONIX IV (PROTONIX IV).
Pantoprazole is a proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of the H+/K+-ATPase enzyme system at the secretory surface of gastric parietal cells.
| Metabolism | Extensively metabolized in the liver via CYP2C19 and CYP3A4 isoenzymes. |
| Excretion | Primarily hepatic metabolism; 71-82% of dose excreted in urine as metabolites, 18-20% in feces. |
| Half-life | 1-2 hours in healthy subjects; prolonged to 3.5-8 hours in hepatic impairment. |
| Protein binding | 96-98% bound to albumin. |
| Volume of Distribution | Approximately 0.15-0.3 L/kg; indicates distribution primarily in extracellular fluid. |
| Bioavailability | Oral bioavailability is approximately 77% (not applicable to IV formulation; IV has 100% bioavailability). |
| Onset of Action | Intravenous: Onset of acid suppression occurs within 30-60 minutes; maximal effect by 1-2 hours. |
| Duration of Action | Acid suppression persists for up to 24 hours following a single IV dose; duration is dose-dependent. |
| Molecular Weight | 383.37 Da |
40 mg intravenously once daily for 7-10 days; for pathological hypersecretory conditions, initial dose 80 mg IV every 12 hours, titrate per acid output.
| Dosage form | INJECTABLE |
| Renal impairment | No dosage adjustment necessary for renal impairment; use caution in severe renal impairment (CrCl <10 mL/min). |
| Liver impairment | For Child-Pugh Class A: 40 mg IV once daily; Class B and C: dose reduction to 20 mg IV once daily is recommended. |
| Pediatric use | 1-16 years: weight-based dosing: 5-10 kg: 5 mg IV once daily; 10-20 kg: 10 mg IV once daily; ≥20 kg: 20 mg IV once daily. Maximum 40 mg IV once daily. |
| Geriatric use | No specific geriatric dose adjustment; monitor renal function and consider lower starting doses due to decreased renal function. |
| 1st trimester | Limited human data; animal studies show no teratogenicity at clinically relevant doses. Risk cannot be excluded. |
| 2nd trimester | No evidence of harm; use if clearly needed. |
| 3rd trimester | No evidence of harm; use if clearly needed. |
Clinical note
Comprehensive clinical and safety monograph for PROTONIX IV (PROTONIX IV).
| Placental transfer | Pantoprazole crosses the placenta in animal studies; human data limited but suggests low transfer. |
| Breastfeeding | Pantoprazole is excreted into human milk in low concentrations; clinical studies show no adverse effects on nursing infants. Use caution in preterm infants or those with renal impairment. |
| Lactation Rating |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
Hypersensitivity to pantoprazole or any component of the formulationConcomitant use with rilpivirine-containing products
| Precautions | Clostridium difficile-associated diarrhea, Bone fracture risk with long-term use, Hypomagnesemia with prolonged use, Acute interstitial nephritis, Cutaneous lupus erythematosus, Cyanocobalamin deficiency with long-term use, Atrophic gastritis risk with long-term use |
| Food/Dietary | No direct food interactions with IV administration. However, concurrent use with other PPIs or acid-suppressing agents is not recommended. Avoid alcohol and spicy foods if they exacerbate GERD symptoms. |
Loading safety data…
| L2 |
| Teratogenic Risk | Pregnancy Category B. Animal studies have not demonstrated fetal risk, but no adequate human studies in pregnant women. Crosses placenta; risk in first trimester unknown. Use only if clearly needed. |
| Fetal Monitoring | No specific monitoring required; standard obstetric care. Assess for adverse maternal effects (e.g., hypomagnesemia with prolonged use). |
| Fertility Effects | No known impairment of fertility based on animal studies. No human data. |
| Clinical Pearls |
| PROTONIX IV (pantoprazole) is a proton pump inhibitor (PPI) indicated for short-term treatment (7-10 days) of gastroesophageal reflux disease (GERD) with erosion when oral therapy is not feasible. Administer intravenously over 15 minutes; do not mix with other drugs. Reconstitute with 10 mL of 0.9% NaCl (final concentration 4 mg/mL). For continuous infusion, dilute in 100 mL and infuse over 10 minutes. Monitor for hypomagnesemia with prolonged use. Avoid use in patients with known hypersensitivity to PPIs or substituted benzimidazoles. |
| Patient Advice | This medication is given through a vein and is used for a short time until you can take pills. · Tell your healthcare provider if you have any allergies, especially to other acid-reducing medications. · Report any signs of allergic reaction such as rash, itching, or swelling of the face, throat, or difficulty breathing. · Inform your doctor about all other medicines you are taking, including prescription, over-the-counter, vitamins, and herbal supplements. · Do not take any additional antacids or acid reducers unless directed by your doctor. |